Table 2.
Group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
---|---|---|---|---|---|---|---|---|
Cyclophosphamide | – | 25 | 50 | 75 | – | 25 | 50 | 75 |
Imatinib | – | – | – | – | 7.5 | 7.5 | 7.5 | 7.5 |
Blastocysts examined | 77 | 62 | 53 | 57 | 70 | 73 | 67 | 28 |
Mean cell number (SD) | 57.8 (23.7) | 75.9 (31.8) | 60.5 (26.3) | 66.2 (24.5) | 73.4 (27.4) | 75.3 (25.9) | 60.2 (28.3) | 57.5 (20.9) |
P Valueb | – | <.001 | NS | NS | <.01 | <.001 | NS | NS |
P Valuec | – | – | – | – | – | NS | NS | <.05 |
Total cell number | 4451 | 4704 | 3206 | 3773 | 5163 | 5695 | 4036 | 1611 |
Cells with positive signal | 148 | 107 | 122 | 100 | 219 | 99 | 149 | 73 |
Percent apoptotic cells, % | 3.33 | 2.27 | 3.81 | 2.65 | 4.24 | 1.74 | 3.69 | 4.53 |
P Valued | – | <.01 | NS | NS | <.05 | <.001 | NS | <.05 |
P Valuee | – | – | – | – | – | NS | NS | <.001 |
Abbreviations: NS, not significant; SD, standard deviation.
a Doses indicate mg/kg body weight.
b When compared to untreated controls (group 1) by the Student t test.
c When compared to imatinib control (ie, between groups 2 and 6, between groups 3 and 7, and between groups 4 and 8) by the Student t test.
d When compared to untreated controls (group 1) by the chi-square test.
e When compared to imatinib control (ie between groups 2 and 6, between groups 3 and 7, and between groups 4 and 8) by the chi-square test.